pharmaphorum February 19, 2024
Phil Taylor

Around 1,000 people with Parkinson’s disease will be able to access treatment with AbbVie’s Produodopa, the first therapy that can be delivered by a 24-hour subcutaneous infusion pump, according to NHS England.

Produodopa (foslevodopa/foscarbidopa) can now be used only for patients in the later stages of Parkinson’s who have stopped responding to standard oral treatment and may have to take more than 20 tablets a day – or receive therapy via a feeding tube – to try to control symptoms.

The treatment takes the form of a small and portable infusion pump that delivers the active ingredients over a 24-hour period and can be refilled at home by patients or their carers. AbbVie also supplies the feeding tube product, called...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Patient / Consumer, Pharma, Pharma / Biotech, Provider
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
New AI model can estimate a person's true biological age from five drops of blood
Spotiphy AI Tool Enhances Spatial Transcriptomics for Precision Medicine
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
FDA Approves First Biosimilar to Omalizumab

Share This Article